VBI Vaccines Inc.

Informe acción OTCPK:VBIV.Q

Capitalización de mercado: US$14.3k

VBI Vaccines Resultados de beneficios anteriores

Pasado controles de criterios 0/6

VBI Vaccines's earnings have been declining at an average annual rate of -17.4%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 22.3% per year.

Información clave

-17.4%

Tasa de crecimiento de los beneficios

16.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.0%
Tasa de crecimiento de los ingresos22.3%
Rentabilidad financieran/a
Margen neto-892.5%
Última actualización de beneficios31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

Sep 22

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

Sep 15

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

Sep 08

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09
Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24
Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Desglose de ingresos y gastos

Cómo gana y gasta dinero VBI Vaccines. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

OTCPK:VBIV.Q Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Mar 249-84379
31 Dec 239-94429
30 Sep 238-1154910
30 Jun 232-1195414
31 Mar 231-1205816
31 Dec 221-1135616
30 Sep 221-1115318
30 Jun 221-1024816
31 Mar 220-734315
31 Dec 211-703820
30 Sep 211-663319
30 Jun 211-632921
31 Mar 211-562319
31 Dec 201-462115
30 Sep 201-421714
30 Jun 202-451515
31 Mar 202-491420
31 Dec 192-551426
30 Sep 194-632032
30 Jun 194-622137
31 Mar 194-662141
31 Dec 183-642138
30 Sep 181-561535
30 Jun 181-501330
31 Mar 181-431223
31 Dec 171-391221
30 Sep 171-36919
30 Jun 171-331017
31 Mar 171-311014
31 Dec 161-23910
30 Sep 160-1996
30 Jun 160-31816
31 Mar 161-25614
31 Dec 151-2651
30 Sep 152-23514
30 Jun 152-631
31 Mar 152-631
31 Dec 143-631
31 Dec 132-931

Ingresos de calidad: VBIV.Q is currently unprofitable.

Margen de beneficios creciente: VBIV.Q is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: VBIV.Q is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.

Acelerando crecimiento: Unable to compare VBIV.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: VBIV.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rentabilidad financiera

Alta ROE: VBIV.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado